Executives On The Move: Bio/Med Changes Made From Lilly And Amgen, And A Step Up R&D Ladder At Daiichi Sankyo
Eli Lilly & Co’s Biology VP takes on SVP, Discovery role at gene regulatory mechanism firm Fulcrum Therapeutics, and Amgen Med Affairs exec becomes CMO at Matinas BioPharma Holdings. At Daiichi Sankyo, R&D leader steps up to Global Head, R&D position.
You may also be interested in...
The pharma, biotech and allied industries came together in London on 4 December to celebrate another year of achievement at the 15th Annual Scrip Awards, hosted by the broadcaster Fiona Bruce.
We are delighted to announce the shortlist for the 15th Annual Scrip Awards.
The financing, which brings the total raised by Juvenescence to $165m, comes as longevity R&D programs supported by the company move towards human testing.